RBCC Opens Talks to Help Develop Revolutionary Breakthrough in $60 Billion Drug Delivery Market

  RBCC Opens Talks to Help Develop Revolutionary Breakthrough in $60 Billion
  Drug Delivery Market

Business Wire

NOKOMIS, Fla. -- February 27, 2013

Rainbow Coral Corp. (OTCBB: RBCC) biotech division Rainbow BioSciences is
currently in talks to help develop and market a revolutionary,
sustained-release drug delivery platform that could soon make local delivery
of biologic agents and small molecules safer, more effective and more
convenient than ever before.

The company is currently working on a potential joint venture agreement with a
privately held drug delivery company developing the novel technology. The
delivery platform is being engineered to solve the problems posed by systemic
drug delivery, including oral and IV delivery. In many cases, systemically
delivered drugs can’t reach sufficient concentrations in target organs to be
effective without damaging the liver, kidneys or heart. Often, systemic
delivery also requires frequent, expensive injections.

The technology RBCC is currently reviewing has the potential to enable
selective, site-specific delivery, allowing for lower drug concentrations and
greatly reducing the risk of drug toxicity.

“Because it’s a sustained-release delivery system, patients could potentially
only need one injection every six months,” said RBCC CEO Patrick Brown. “In
addition to helping millions of patients struggling with chronic conditions,
the technology also has the benefit of extending the patent life cycles of
drugs, giving potential pharmaceutical partners a tremendous market

“RBCC hopes to conclude its due diligence work on the drug delivery company
and sign a joint venture agreement to begin getting the new technology into
doctors’ hands in the next few weeks,” Brown added.

For more information on Rainbow BioSciences’ current projects, please

Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Bristol Myers Squibb Co.
(NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT)
and Amgen Inc. (NASDAQ:AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit www.RainbowBioSciences.com. For investment information and
performance data on the Company, please

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.


Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
Press spacebar to pause and continue. Press esc to stop.